ArticleFrontiers in chemistry2025
Insights into the pro-angiogenic effect of hydroxysafflor yellow A (HSYA): targeting HIF-1α and MMP9 in HMEC-1.
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiogenesis is a fundamental physiological process mediating vascular network formation, represents a critical therapeutic target for ischemic diseases and tumor neovascularization. Xuefu Zhuyu decoction (XFZYD), a classical formula for promoting blood circulation and resolving stasis, demonstrates pro-angiogenic effect with safflower functioning as the sovereign herb. Hydroxysafflor yellow A (HSYA), the primary bioactive constituent of safflower, exerts potent angiogenesis modulation, defining its pharmacological significance. Methods: In this study, Results: HSYA exerted concentration-dependent pro-angiogenic effects on HMEC-1 cells over 24 h without compromising cell viability ( Conclusion: HSYA demonstrates significant pro-angiogenic activity on HMEC-1. Mechanistically, HSYA modulates multiple signaling pathways, with HIF-lα and MMP9 demonstrating regulatory significance. These findings suggest a molecular basis for HSYA's therapeutic potential in ischemic vascular pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.